Will Cytokinetics New HCM Drug Challenge Camzyos?

2 weeks ago 15

Cytokinetics, a San Francisco biotech company, is hoping that its experimental HCM drug, aficamten, will soon be a competitor to Bristol Myers Squibb's first-in-class myosin inhibitor Camzyos (mavacamten).

View Entire Post

Read Entire Article